HaploX Secures CAP-RNA-A Certification and Expands Strategic Collaboration with Xinhelai Biosciences and MGI
NeoCura
RNA Innovative Drug Developer
Recently, regardingHaploxThe news kept coming continuously.
First, the Shenzhen and Hong Kong laboratories both receivedCAP-RNA-AAuthoritative certification, having achieved a perfect score in over 300 consecutive assessments by CAP (College of American Pathologists), CLIA (Clinical Laboratory Improvement Amendments),EMQNEMQN (European Molecular Genetics Quality Network), NCCL (National Center for Clinical Laboratories under the National Health Commission) and other domestic and international External Quality Assessment (EQA) programs are among the few in China."Double C" CertificationThe enterprise has gained significant recognition in the field of genetic testing services.
Next, withNeoCuraEstablish a strategic partnership to deepen industrial layout and expand the boundaries of technology application. NeoCura is a pioneer in the field of mRNA tumor innovative drug research in China. The collaboration between the two partiesCan promote the vertical development of the industry, accelerating the clinical translation of mRNA tumor vaccines with high-throughput sequencing platforms.Haplox's capabilities in gene sequencing and big data analysis can also effectively enhance the precision of NeoCura's innovative drug development, advancing collaborations in AI-driven pharmaceuticals and precision medicine.
Continuous positive progress has kept Haplox in the spotlight. With core technological advantages in areas such as gene sequencing, liquid biopsy, life information, and big data, its business spans across the entire cancer management process, genetic disease screening, major infectious diseases, and more, making it a frequent focal point of attention.
Since the suspension of its IPO at the Hong Kong Stock Exchange in 2023, Haplox has been showcasing new competitiveness in its own way, with a dual focus on "C" and deeper development towards pharmaceutical companies.It is just one of the manifestations.
Looking Back on the Past, What is the Real Harvest
From 2020 to 2022, Haplox's operating revenue was RMB 1.00 billion, RMB 4.87 billion, and RMB 16.76 billion, with corresponding net profits of -RMB 0.66 billion, RMB 0.67 billion, and RMB 1.58 billion. The high proportion of its COVID-19 nucleic acid testing business made it an overnight sensation, almost a household name in Shenzhen.
In view of the previous recognition of gene detection technology, Haplox also actively participated in the anti-epidemic efforts, resulting in the aforementioned substantial achievements and earning sufficient honors.
Looking back at its inception, when gene sequencing was still in its nascent stage and regulatory oversight was not yet well-established, Haplox adopted a high-profile and aggressive approach, focusing on...Full-cycle Genetic Testing Technology, while also engaging in early cancer screening.
At that time, there were two considerations: First, gene detection technology can look more microscopically, allowing personalized treatment based on cancer gene profiling, whereas traditional imaging can only identify cancer cell clusters larger than 4mm. It can also monitor residual small numbers of cancer cells, reducing the risk of cancer recurrence. Second,Gene detection technology can detect diseases at an early stage or even before they occur, moving prevention and treatment forward.。
At that time, HaploxNGSTechnology takes the lead, with a market share reaching 4.7%. In the NGS business, it holds nearly 40% of the share, ranking second in China. With this technology, it not only brings new solutions to cancer patients but also offers new approaches for many pharmaceutical companies in drug development, covering both LDT and IVD models.The core technology and foundation developed independently enable it to continue growing post-pandemic.
After the first IVD product under its umbrella was approved in 2021, Haplox successively secured Series C and Series D financing in 2023, officially advancing toward the capital market. Clearly, the revenue generated from nucleic acid testing can only be a bonus. Looking ahead, whether or not there is an IPO plan in the future, the key lies in the evolution of genetic testing technologies, the launch of competitive products, as well as the expansion into laboratory testing.Intelligent upgrades and quality control are becoming increasingly better.That's the highlight.
Walking with Giants
In 2024, Haplox and MGI Tech established a strategic partnership, marking the official launch of the Haplox-MGI Tech DCS Lab Omics Frontier Laboratory, ushering in a new phase of development. The two parties will collaborate on high-throughput nanoball sequencing, cellular omics, spatiotemporal omics, and other cutting-edge technologies. MGI Tech, known as the Chinese version of Illumina, is rapidly gaining prominence in the field of instrumentation and is poised to challenge for international leadership.
For Haplox,Is a significant recognition. The laboratory is equipped with BGI's DNBSEQ-T7 and DNBelab C-TaiM 4 Single-Cell Droplet Generator.Advanced equipmentBy utilizing controllable domestically-produced equipment, its proprietary technologies such as liquid biopsy, bioinformatics, and big data can be fully leveraged, enabling researchers to simultaneously process samples in batches and conduct systematic research across multiple dimensions including DNA, cells, and tissues.Greatly Enhance Research Efficiency。
The strength to stand alongside giants is thanks to the strategic foresight at the startup phase, such as the full-cycle genetic testing technology mentioned above. Whether in auxiliary diagnosis, prognostic monitoring, early screening, or other fields like plants, animals, and microorganisms, it has proven useful in research tasks.This is one of the reasons why laboratories can frequently achieve excellent results today. Every single step has the opportunity to develop into a unique competitive advantage.
Now, it only awaits further capital empowerment. In terms of technical products, industry evaluations suggest that aside from BGI, Haplox has the most comprehensive business coverage in NGS. It successively completed: Angel Round financing of 10 million yuan from Pangu Venture Capital; Series A financing of 50 million yuan in 2016; the commercialization of its first LDT and securing Series A+ financing of 77.5 million yuan in 2017; Series B financing of 100 million yuan in 2018; Series B+ financing of 15 million yuan in 2020; Series C financing of approximately 180 million yuan in 2021; and completed Series D financing in 2023.
Perhaps it is not only because of the current downturn in the market. NGS technology or more cutting-edge multi-omics technologies need AI empowerment to keep up with the times. We look forward to more positive information.
Written at the end
Relying on comprehensive gene detection technology, Haplox's Shenzhen and Hong Kong laboratories have obtained international authoritative certifications such as CAP-RNA-A (with over 300 perfect passes in quality assessments both in and outside China).Becoming a "Double C" certified enterprise in China, establishing credibility in the genetic testing field, and with strategic cooperation from MGI Tech, Haplox is bound to stay ahead in cutting-edge innovation and keep up with the times.。
Although there has been no progress regarding the suspension of the IPO, whether capital empowerment is necessary is not a mandatory choice but rather depends on the appropriate stage and needs. The company is currently reshaping its competitiveness through technological upgrades (AI-powered multi-omics), laboratory intelligence, and in-depth cooperation with pharmaceutical enterprises, highlighting its sustainable layout in fields such as whole-course tumor management and genetic disease screening. When technological iteration requires substantial resources, restarting the IPO could be a viable option.
References:
1. Haplox Official Website, Related Information
2.30 Years Old Entrepreneur in Shenzhen, Haplox Earned Nearly 2 Billion Yuan in Three Years of Nucleic Acid Testing, Hard Kr, 2025
3. What is the secret to Haplox's rapid development?, Little Orange Lantern Network, 2024